Day One Biopharmaceuticals Files 8-K
Ticker: DAWN · Form: 8-K · Filed: Jun 18, 2024 · CIK: 1845337
Sentiment: neutral
Topics: sec-filing, listing-status
Related Tickers: DAWN
TL;DR
DAY ONE BIOPHARMACEUTICALS (DAWN) filed an 8-K confirming its Nasdaq listing.
AI Summary
On June 17, 2024, Day One Biopharmaceuticals, Inc. filed an 8-K report. The filing primarily serves as a notification of the company's status and registered securities. It confirms the company's common stock is traded on the Nasdaq Global Select Market under the symbol DAWN.
Why It Matters
This filing is a routine disclosure that confirms the company's listing and trading status on a major exchange, providing transparency for investors.
Risk Assessment
Risk Level: low — This filing is a standard procedural disclosure and does not contain new material financial or operational information.
Key Players & Entities
- Day One Biopharmaceuticals, Inc. (company) — Registrant
- June 17, 2024 (date) — Date of earliest event reported
- DAWN (company) — Trading Symbol
- Nasdaq Global Select Market (company) — Exchange
FAQ
What is the primary purpose of this 8-K filing for Day One Biopharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report current information as required by the SEC, specifically confirming the company's registered securities and their listing on the Nasdaq Global Select Market.
What is the trading symbol for Day One Biopharmaceuticals, Inc.'s common stock?
The trading symbol for Day One Biopharmaceuticals, Inc.'s common stock is DAWN.
On which exchange is Day One Biopharmaceuticals, Inc.'s common stock registered?
Day One Biopharmaceuticals, Inc.'s common stock is registered on the Nasdaq Global Select Market.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is June 17, 2024.
Does this filing indicate any new financial performance or strategic changes for Day One Biopharmaceuticals, Inc.?
No, this filing is a routine current report and does not indicate any new financial performance or strategic changes; it primarily confirms existing registration and trading information.
Filing Stats: 916 words · 4 min read · ~3 pages · Grade level 11 · Accepted 2024-06-18 08:36:09
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share DAWN Nasdaq Global Select
- $55.0 million — an upfront license fee in the amount of $55.0 million. Further, pursuant to the License Agree
- $1.15 billion — eligible to receive up to an additional $1.15 billion in development, regulatory and commerci
Filing Documents
- d804506d8k.htm (8-K) — 30KB
- d804506dex991.htm (EX-99.1) — 11KB
- d804506dex992.htm (EX-99.2) — 57KB
- g804506ex99_2p10g1.jpg (GRAPHIC) — 269KB
- g804506ex99_2p11g1.jpg (GRAPHIC) — 253KB
- g804506ex99_2p12g1.jpg (GRAPHIC) — 250KB
- g804506ex99_2p13g1.jpg (GRAPHIC) — 464KB
- g804506ex99_2p14g1.jpg (GRAPHIC) — 203KB
- g804506ex99_2p15g1.jpg (GRAPHIC) — 241KB
- g804506ex99_2p16g1.jpg (GRAPHIC) — 242KB
- g804506ex99_2p17g1.jpg (GRAPHIC) — 244KB
- g804506ex99_2p18g1.jpg (GRAPHIC) — 225KB
- g804506ex99_2p19g1.jpg (GRAPHIC) — 224KB
- g804506ex99_2p1g1.jpg (GRAPHIC) — 261KB
- g804506ex99_2p20g1.jpg (GRAPHIC) — 299KB
- g804506ex99_2p21g1.jpg (GRAPHIC) — 227KB
- g804506ex99_2p22g1.jpg (GRAPHIC) — 395KB
- g804506ex99_2p23g1.jpg (GRAPHIC) — 344KB
- g804506ex99_2p24g1.jpg (GRAPHIC) — 282KB
- g804506ex99_2p25g1.jpg (GRAPHIC) — 245KB
- g804506ex99_2p26g1.jpg (GRAPHIC) — 199KB
- g804506ex99_2p27g1.jpg (GRAPHIC) — 222KB
- g804506ex99_2p28g1.jpg (GRAPHIC) — 254KB
- g804506ex99_2p29g1.jpg (GRAPHIC) — 270KB
- g804506ex99_2p2g1.jpg (GRAPHIC) — 479KB
- g804506ex99_2p30g1.jpg (GRAPHIC) — 259KB
- g804506ex99_2p31g1.jpg (GRAPHIC) — 302KB
- g804506ex99_2p32g1.jpg (GRAPHIC) — 61KB
- g804506ex99_2p33g1.jpg (GRAPHIC) — 285KB
- g804506ex99_2p34g1.jpg (GRAPHIC) — 293KB
- g804506ex99_2p35g1.jpg (GRAPHIC) — 372KB
- g804506ex99_2p36g1.jpg (GRAPHIC) — 261KB
- g804506ex99_2p37g1.jpg (GRAPHIC) — 321KB
- g804506ex99_2p38g1.jpg (GRAPHIC) — 302KB
- g804506ex99_2p39g1.jpg (GRAPHIC) — 238KB
- g804506ex99_2p3g1.jpg (GRAPHIC) — 368KB
- g804506ex99_2p40g1.jpg (GRAPHIC) — 352KB
- g804506ex99_2p41g1.jpg (GRAPHIC) — 256KB
- g804506ex99_2p42g1.jpg (GRAPHIC) — 247KB
- g804506ex99_2p43g1.jpg (GRAPHIC) — 257KB
- g804506ex99_2p44g1.jpg (GRAPHIC) — 298KB
- g804506ex99_2p45g1.jpg (GRAPHIC) — 321KB
- g804506ex99_2p4g1.jpg (GRAPHIC) — 264KB
- g804506ex99_2p5g1.jpg (GRAPHIC) — 253KB
- g804506ex99_2p6g1.jpg (GRAPHIC) — 211KB
- g804506ex99_2p7g1.jpg (GRAPHIC) — 382KB
- g804506ex99_2p8g1.jpg (GRAPHIC) — 265KB
- g804506ex99_2p9g1.jpg (GRAPHIC) — 385KB
- g804506g0618084810522.jpg (GRAPHIC) — 3KB
- 0001193125-24-163081.txt ( ) — 17669KB
- dawn-20240617.xsd (EX-101.SCH) — 3KB
- dawn-20240617_lab.xml (EX-101.LAB) — 18KB
- dawn-20240617_pre.xml (EX-101.PRE) — 11KB
- d804506d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, regarding the License Agreement, dated June 18, 2024. 99.2 Corporate Presentation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DAY ONE BIOPHARMACEUTICALS, INC. Date: June 18, 2024 By: /s/ Charles N. York II, M.B.A. Charles N. York II, M.B.A. Chief Operating Officer and Chief Financial Officer